Non-IgA mesangioproliferative glomerulonephritis: a benign entity?

• Published in: Nephrology, dialysis, transplantation Vol. 27; no. 6; pp. 2322 - 2327
• Main Authors: Waikhom, Rajesh, Sarkar, Dipankar, Patil, Krishna, Pandey, Rajendra, Dasgupta, Sanjay, Jadhav, Jayaprada, Abraham, Anila
• Format: Journal Article
• Language: English
• Published: England 01.06.2012
• Subjects: Adult; Biopsy; Child; Drug Resistance; Female; Follow-Up Studies; Glomerular Filtration Rate; Glomerulonephritis, Membranoproliferative - complications; Glomerulonephritis, Membranoproliferative - drug therapy; Humans; Immunoglobulin A - immunology; Kidney Failure, Chronic - etiology; Kidney Failure, Chronic - pathology; Male; Nephrotic Syndrome - etiology; Nephrotic Syndrome - pathology; Prognosis; Steroids - adverse effects
• ISSN: 1460-2385
• DOI: 10.1093/ndt/gfr653

Non-IgA mesangioproliferative glomerulonephritis is a well recognized but less studied entity. The clinical manifestations, treatment response and long-term outcome have not been clearly defined. This single-centre study included patients with biopsy-proven non-IgA mesangioproliferative glomerulonephritis who had been on regular follow-up for >3 years. Their clinical features at presentation, response to therapy and long-term renal outcome are addressed in this study. Nephrotic syndrome developed in 51 of 57 patients (89.4%). The majority of them--34 of 51(80%)--were steroid sensitive and had either infrequent or no relapse. However, steroid-dependent nephrotic syndrome occurred in eight patients (15.6%), while steroid resistance occurred in nine patients (17.6 %). Thirteen patients developed chronic kidney disease (CKD) with three progressing to end-stage renal disease, three to CKD Stage 4 and seven to CKD Stage 3. Non-IgA mesangioproliferative glomerulonephritis is a disease, which is not benign, and is associated with significant treatment-related morbidity.